Pfizer’s anti-TNF-alpha Nanobody, ATN-103, is currently in a Phase II study in patients with rheumatoid arthritis (RA) and it has completed recruitment for the Phase II study.
Ablynx entered into an exclusive research collaboration and license agreement in November 2006 with Wyeth, which was acquired by Pfizer.
As per the terms of the agreement, Pfizer now owns the exclusive development and commercialisation rights to the anti-TNF-alpha Nanobody programme.
Ablynx chairman and CEO Edwin Moses said that Pfizer’s decision to advance a second anti-TNF-alpha Nanobody into the clinic underscores the importance and potential of this programme.
"We are very pleased with the progress made in this TNF-alpha partnership, and we continue to work with Pfizer to discover additional anti-TNF-alpha Nanobodies which could have important therapeutic applications," Moses said.